最近搜索:細胞培養(yǎng) 微生物學 分子生物 生物化學
    首頁>>免疫學>>一抗>>磷酸化蛋白酪氨酸激酶JAK-2抗體
    磷酸化蛋白酪氨酸激酶JAK-2抗體
    • 產(chǎn)品貨號:
      BN40820R
    • 中文名稱:
      磷酸化蛋白酪氨酸激酶JAK-2抗體
    • 英文名稱:
      Rabbit anti-phospho-JAK2 (Tyr1007+Tyr1008) Polyclonal antibody
    • 品牌:
      Biorigin
    • 貨號

      產(chǎn)品規(guī)格

      售價

      備注

    • BN40820R-100ul

      100ul

      ¥2470.00

      交叉反應:Human,Mouse,Rat,Zebrafish(predicted:Chicken,Pig,Rabbit) 推薦應用:IHC-P,IHC-F,ICC,IF,Flow-Cyt,ELISA

    產(chǎn)品描述

    英文名稱phospho-JAK2 (Tyr1007+Tyr1008)
    中文名稱磷酸化蛋白酪氨酸激酶JAK-2抗體
    別    名JAK2 (phospho Y1007); p-JAK2 (phospho Y1007); JAK2 (phospho Y1007 + Y1008); p-JAK2 (phospho Y1007 + Y1008); JAK2(Phospho-Tyr1007/1008); Tyrosine protein kinase JAK2; JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating Kinase 2; Janus Kinase 2; JTK 10; JTK10; OTTHUMP00000043260; Tyrosine-protein kinase JAK2; Tyrosine protein kinase JAK2.  



    產(chǎn)品類型磷酸化抗體 
    研究領域腫瘤  細胞生物  染色質(zhì)和核信號  信號轉(zhuǎn)導  激酶和磷酸酶  表觀遺傳學  
    抗體來源Rabbit
    克隆類型Polyclonal
    交叉反應Human, Mouse, Rat,  (predicted: Chicken, Pig, Rabbit, Daniorerio,)
    產(chǎn)品應用ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/Test ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復)
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    分 子 量131kDa
    細胞定位細胞核 細胞漿 細胞膜 
    性    狀Liquid
    濃    度1mg/ml
    免 疫 原KLH conjugated Synthesised phosphopeptide derived from human JAK2 around the phosphorylation site of Tyr1007/1008:KE(p-Y)(p-Y)KV 
    亞    型IgG
    純化方法affinity purified by Protein A
    儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
    PubMedPubMed
    產(chǎn)品介紹JAK2 (Janus Activating Kinase 2) is a tyrosine kinase of the non-receptor type, that associates with the intracellular domains of cytokine receptors; JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin; it has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. Ligand binding to a variety of cell surface receptors (e.g., cytokine, growth factor, GPCRs) leads to an association of those receptors with JAK proteins, which are then activated via phosphorylation on tyrosines 1007 and 1008 in the kinase activation loop. Activated JAK proteins phosphorylate and activate STAT (signal transducers and activators of transcription) proteins, which then dimerize and translocate to the nucleus. Once in the nucleus, STAT proteins bind to DNA and modify the transcription of various genes.

    Function:
    Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.

    Subunit:
    Interacts with EPOR, LYN, SIRPA, SH2B1 and TEC. Interacts with IL23R, SKB1 and STAM2.

    Subcellular Location:
    Endomembrane system; Peripheral membrane protein. Cytoplasm. Nucleus.

    Tissue Specificity:
    Ubiquitously expressed throughout most tissues.

    Post-translational modifications:
    Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity. Also phosphorylated by TEC.

    DISEASE:
    Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
    Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:600880]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.

    Similarity:
    Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
    Contains 1 SH2 domain.

    SWISS:
    O60674

    Gene ID:
    3717

    Database links:

    Entrez Gene: 3717 Human

    Entrez Gene: 16452 Mouse

    Entrez Gene: 24514 Rat

    GenBank: NP_004963 Human

    Omim: 147796 Human

    SwissProt: O60674 Human

    SwissProt: Q62120 Mouse

    SwissProt: Q62689 Rat

    Unigene: 656213 Human

    Unigene: 275839 Mouse

    Unigene: 18909 Rat



    Important Note:
    This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

    激酶和磷酸酶(Kinases and Phosphatases)


    亚洲精品久久无码av片俺去也| 亚洲国产另类久久久精品黑人| 国产亚洲精品自在线观看| 亚洲精品美女久久7777777| 亚洲一区中文字幕在线观看| 久久亚洲精品国产精品| 亚洲国产精品自在线一区二区| 国产成A人亚洲精V品无码| 久久亚洲精品视频| 亚洲春色在线视频| 亚洲AV无码不卡在线播放| 国产亚洲欧洲精品| 亚洲AV成人片色在线观看高潮| 国产成人亚洲精品青草天美| 精品久久香蕉国产线看观看亚洲| 亚洲精品自产拍在线观看| 亚洲国产成人一区二区精品区| 亚洲无码在线播放| 亚洲av午夜福利精品一区人妖| 久久噜噜噜久久亚洲va久| 亚洲欧洲在线观看| 亚洲高清日韩精品第一区| 亚洲成aⅴ人在线观看| 亚洲av乱码一区二区三区香蕉| 亚洲人成人77777网站不卡| 成人区精品一区二区不卡亚洲| 亚洲日韩精品无码专区| 亚洲欧好州第一的日产suv| 国产AV无码专区亚洲AV蜜芽| 亚洲VA综合VA国产产VA中| 久久精品国产精品亚洲人人| 久久亚洲高清观看| 亚洲一区免费观看| 亚洲五月综合网色九月色| 亚洲精品无码久久久久A片苍井空| 99亚洲精品卡2卡三卡4卡2卡| 亚洲国产婷婷香蕉久久久久久| 久久久久亚洲AV成人网| 亚洲成a人片在线观看日本| 亚洲精品国产福利在线观看| 亚洲精品国产日韩|